Shaan Opens Up About Prostate Cancer Scare: All You Need To Know About It
Bollywood playback singer Shaan recently opened up about a personal health scare he experienced in 2020. Speaking at the launch of MenCan, an initiative by the Tata Memorial Centre's Urologic Oncology Disease Management Group (URO DMG), Shaan revealed that he once feared he might have prostate cancer—but fortunately, it turned out to be a 'false alarm.'
Shaan used the platform to highlight the importance of regular medical check-ups and early detection. 'I had a bit of a prostate scare in 2020, which I want to share with you. It almost led to a point where I was told by a few doctors that this could be prostate cancer, but it turned out it was a false alarm," he told reporters at the event.
He went on to explain how the incident changed his approach to health. 'Since then, I've been very, very careful in terms of getting my regular tests done. And that is something that I've done on a personal level, which again, when I share with my friends, it's very ticklish, it's very funny. Therefore, I realised that it's something that we need to, you know, create more awareness about," he said.
Shaan emphasised the stigma associated with male-specific cancers such as prostate, testicular, or penile cancer. He pointed out that many people perceive it as a 'scary word" and often avoid even mentioning it. He stressed that this fear and societal taboo are exactly what needs to be addressed and changed.
The singer mentioned that the screening process can feel invasive and intimidating, but emphasised the need to overcome that fear. Shaan highlighted that men's health is essential not only for the individual but also for their families and loved ones. He ended by affirming that it's important to speak openly and raise awareness about diseases like prostate cancer.
Can Prostate Cancer Be Prevented?
While there's no guaranteed way to prevent prostate cancer, these healthy habits may lower your risk:
Regular Screenings: Talk to your doctor about how often to get tested, especially if you have risk factors.
Maintain a Healthy Weight: Discuss a safe, sustainable weight goal with your healthcare provider.
Stay Active: Aim for at least 150 minutes of moderate exercise weekly, just over 20 minutes per day.
Eat a Balanced Diet: Prioritise fruits, vegetables and whole grains. Limit red or processed meats.
Avoid Smoking: If you smoke, seek support to quit. Smoking increases the risk of several diseases, including prostate cancer.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hindustan Times
6 hours ago
- Hindustan Times
Maharashtra cabinet waives stamp duty for proposed cancer hospital in Raigad
Mumbai, In a move aimed at expanding healthcare infrastructure in Maharashtra, the state cabinet on Tuesday approved a complete stamp duty waiver for a proposed cancer hospital by Tata Memorial Centre in Raigad district. Maharashtra cabinet waives stamp duty for proposed cancer hospital in Raigad As part of the project, 10 hectares of government land at Tambati in Khalapur taluka has been allotted to the Tata Memorial Centre on a 30-year lease at a nominal rent of ₹1 per year. The stamp duty of ₹38.99 lakh applicable on the lease agreement has been fully waived, it was stated. The centre is establishing an Integrated Ayurvedic Cancer Hospital and Research Centre, which will include a 100-bed facility. At least 12 per cent of beds at the facility will be reserved at subsidised rates under Central and state government health schemes for poor and economically weaker sections. Additionally, accommodation for one attendant per patient will be provided at minimal cost. The decision to waive the stamp duty was taken under provisions of the Maharashtra Stamp Act, with necessary notifications to be issued after consultation with the Law and Judiciary Department. Revenue Minister Chandrashekhar Bawankule, in a statement, said that the waiver will facilitate the expansion of cancer research and treatment services by Tata Memorial Centre and provide quality healthcare access to the general public, especially in rural and semi-urban areas. In another decision, the cabinet approved the regularisation of encroachments at Vengurla Camp Gawaliwada in Sindhudurg district. At least 42 families, most of them from the Gawli community, have been residing on this land since the British era, with structures dating back to 1905, as per a resolution passed by the Vengurla Municipal Council. The residents have been demanding legal ownership of the land and their homes. Under the approved policy, encroachments of up to 1,500 sq ft per household will be regularised free of cost. For any area above 1,500 sq ft, occupants will be required to pay as per the 1989 government valuation rates, to which residents have already consented in meetings with the Sub-Divisional Officer of Sawantwadi. The land will be granted under Occupant Class-2 tenure, meaning it cannot be sold or transferred without the government's permission. The total area under encroachment includes 0.69.32 hectares of built-up land and 2.23.88 hectares of open land, totalling 2.93.20 hectares, excluding religious structures. The move overturns earlier rules from 2002, which mandated payment of 2.5 times the market rate plus interest for regularisation. Bawankule said this decision brings long-awaited justice to generations of the Gawli community, who have lived on this land for decades. It not only resolves a long-pending issue but also sets a precedent for similar cases across the state, he said in a statement. This article was generated from an automated news agency feed without modifications to text.
News18
6 hours ago
- News18
Maharashtra cabinet waives stamp duty for proposed cancer hospital in Raigad
Agency: Mumbai, Aug 19 (PTI) In a move aimed at expanding healthcare infrastructure in Maharashtra, the state cabinet on Tuesday approved a complete stamp duty waiver for a proposed cancer hospital by Tata Memorial Centre in Raigad district. As part of the project, 10 hectares of government land at Tambati in Khalapur taluka has been allotted to the Tata Memorial Centre on a 30-year lease at a nominal rent of Rs 1 per year. The stamp duty of Rs 38.99 lakh applicable on the lease agreement has been fully waived, it was stated. The centre is establishing an Integrated Ayurvedic Cancer Hospital and Research Centre, which will include a 100-bed facility. At least 12 per cent of beds at the facility will be reserved at subsidised rates under Central and state government health schemes for poor and economically weaker sections. Additionally, accommodation for one attendant per patient will be provided at minimal cost. The decision to waive the stamp duty was taken under provisions of the Maharashtra Stamp Act, with necessary notifications to be issued after consultation with the Law and Judiciary Department. In another decision, the cabinet approved the regularisation of encroachments at Vengurla Camp Gawaliwada in Sindhudurg district. At least 42 families, most of them from the Gawli community, have been residing on this land since the British era, with structures dating back to 1905, as per a resolution passed by the Vengurla Municipal Council. The residents have been demanding legal ownership of the land and their homes. Under the approved policy, encroachments of up to 1,500 sq ft per household will be regularised free of cost. For any area above 1,500 sq ft, occupants will be required to pay as per the 1989 government valuation rates, to which residents have already consented in meetings with the Sub-Divisional Officer of Sawantwadi. The land will be granted under Occupant Class-2 tenure, meaning it cannot be sold or transferred without the government's permission. The total area under encroachment includes 0.69.32 hectares of built-up land and 2.23.88 hectares of open land, totalling 2.93.20 hectares, excluding religious structures. The move overturns earlier rules from 2002, which mandated payment of 2.5 times the market rate plus interest for regularisation. Bawankule said this decision brings long-awaited justice to generations of the Gawli community, who have lived on this land for decades. It not only resolves a long-pending issue but also sets a precedent for similar cases across the state, he said in a statement. PTI MR ARU view comments First Published: August 19, 2025, 17:45 IST Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy. Loading comments...
Indian Express
28-07-2025
- Indian Express
Revolutionising disease's treatment: Twin study identifies novel risk genes, molecular subtypes in thyroid cancer among Indians
In a significant leap for cancer research and precision medicine, a twin Indian study has decoded the complex genetic architecture of thyroid cancer — one of the most common endocrine malignancies. Researchers from Tata Memorial Centre and the Department of Genetics, University of Delhi, South Campus, have shed new light on how thyroid cancer behaves in Indian patients, identifying novel risk genes and molecular subtypes that could revolutionise diagnosis and treatment. Both the studies were published back-to-back in 'JCO Global Oncology.' The research is spearheaded by graduate student Vaishakhi Trivedi under the mentorship of Dr Kumar Prabhash and Dr Amit Dutt. 'Our work not only adds data to global cancer databases — it also redefines what is known about thyroid cancer in the Indian population,' Professor Dutt said. The first study concerns papillary thyroid cancer (PTC), which accounts for 80-85 per cent of all thyroid cancer cases in India. This is considered treatable. The team analysed DNA from 100 Indian patients and found mutations in the DUOX2 gene found in nearly nine per cent of cases. 'This gene, previously known for its role in thyroid hormone production, now appears to be a genetic red flag for recurrence and poor prognosis. This is the first time DUOX2 has been implicated as a predisposing factor in PTC. It offers an opportunity for early detection and potentially life-saving interventions,' Prof Dutt said. The study even identified two different subtypes associated with aggressive cancer and high recurrence. The BRAF-RAS-driven subtype makes up 62 per cent of cases and is identified by mutations that are often tied to more aggressive tumour behaviour. The iBR (Independent of BRAF-RAS) subtype is a newly-defined category. 'This group lacks traditional mutations but shows alarming signs of treatment resistance and high recurrence. It is marked by alterations in genes like SMAD4 and TG — a previously uncharted territory for thyroid oncologists,' said Dr Prabhash. This dual classification signals a new era of care where treatments are tailored to the patient's genetic profile rather than a one-size-fits-all approach. While PTC is common and often curable, anaplastic thyroid cancer (ATC) is its deadly cousin — rare, fast-moving and resistant to nearly every treatment in the book. In a separate study, the research team examined 68 samples and found mutations in the THRA gene in 11 per cent of Indian patients with ATC. This is in sharp contrast to Caucasian datasets. 'THRA, a gene tied to thyroid hormone signalling, appears to be a key player in cellular plasticity or the process by which cancer cells morph, lose their identity and become more aggressive. THRA mutations are like flipping the switch. They make the cancer harder to kill but they also give us a target. That's a rare silver lining,' Dr Prabhash explained. These findings offer practical methods of how thyroid cancers are diagnosed, treated and managed in Indian patients. 'Patients with DUOX2 mutations could be monitored proactively, much like BRCA testing in breast cancer. This may help in diagnosing aggressive PTC and ATC early and prevent a relapse,' Prof Dutt said. Researchers also added that therapies that restore THRA function may finally give ATC patients a fighting chance. 'We need a personalised roadmap for thyroid cancer. With the promise of advanced tools like CRISPR gene editing and small-molecule inhibitors, these discoveries could soon migrate from the lab bench to the bedside,' the researchers said. 'Genetic profiling should be as routine as a biopsy,' said Vaishakhi Trivedi. 'We have the science. Now we need the systems to support it.' Anuradha Mascarenhas is a journalist with The Indian Express and is based in Pune. A senior editor, Anuradha writes on health, research developments in the field of science and environment and takes keen interest in covering women's issues. With a career spanning over 25 years, Anuradha has also led teams and often coordinated the edition. ... Read More
